A high-affinity ErbB4Fc fusion protein is a potent antagonist of heregulin-mediated receptor activation

References

• Adams TE, Koziolek EJ, Hoyne PH, Bentley JD, Lu L, Lovrecz G, Ward CW, Lee FT, Scott AM, Nash AD, Rothacker J, Nice EC, Burgess AW, Johns TG. 2009. A truncated soluble epidermal growth factor receptor-Fc fusion ligand trap displays anti-tumour activity in vivo. Growth Factors. 27:141–154.
   Web of Science ®Google Scholar
• Alaoui-Jamali MA, Song DJ, Benlimame N, Yen L, Deng X, Hernandez-Perez M, Wang T. 2003. Regulation of multiple tumor microenvironment markers by overexpression of single or paired combinations of ErbB receptors. Cancer Res. 63:3764–3774.
   PubMed Web of Science ®Google Scholar
• Citri A, Yarden Y. 2006. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 7:505–516.
   PubMed Web of Science ®Google Scholar
• Cockett MI, Bebbington CR, Yarranton GT. 1990. High level expression of tissue inhibitor of metalloproteinases in Chinese hamster ovary cells using glutamine synthetase gene amplification. Biotechnology (N Y). 8:662–667.
   PubMedGoogle Scholar
• Elenius K, Paul S, Allison G, Sun J, Klagsbrun M. 1997. Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation. EMBO J. 16:1268–1278.
   PubMedGoogle Scholar
• Elleman TC, Domagala T, McKern NM, Nerrie M, Lonnqvist B, Adams TE, Lewis J, Lovrecz GO, Hoyne PA, Richards KM, Howlett GJ, Rothacker J, Jorissen RN, Lou M, Garrett TP, Burgess AW, Nice EC, Ward CW. 2001. Identification of a determinant of epidermal growth factor receptor ligand-binding specificity using a truncated, high-affinity form of the ectodomain. Biochemistry. 40:8930–8939.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick VD, Pisacane PI, Vandlen RL, Sliwkowski MX. 1998. Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4. FEBS Lett. 431:102–106.
   PubMed Web of Science ®Google Scholar
• Gilbertson RJ, Perry RH, Kelly PJ, Pearson AD, Lunec J. 1997. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res. 57:3272–3280.
   PubMed Web of Science ®Google Scholar
• Gilbertson RJ, Bentley L, Hernan R, Junttila TT, Frank AJ, Haapasalo H, Connelly M, Wetmore C, Curran T, Elenius K, Ellison DW. 2002. ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Clin Cancer Res. 8:3054–3064.
   PubMed Web of Science ®Google Scholar
• Jin P, Zhang J, Beryt M, Turin L, Brdlik C, Feng Y, Bai X, Liu J, Jorgensen B, Shepard HM. 2009. Rational optimization of a bispecific ligand trap targeting EGF receptor family ligands. Mol Med. 15:11–20.
   Google Scholar
• Jones JT, Ballinger MD, Pisacane PI, Lofgren JA, Fitzpatrick VD, Fairbrother WJ, Wells JA, Sliwkowski MX. 1998. Binding interaction of the heregulinbeta egf domain with ErbB3 and ErbB4 receptors assessed by alanine scanning mutagenesis. J Biol Chem. 273:11667–11674.
   PubMedGoogle Scholar
• Jones JT, Akita RW, Sliwkowski MX. 1999. Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett. 447:227–231.
   PubMed Web of Science ®Google Scholar
• Kim CH, Oh Y, Lee TH. 1997. Codon optimization for high-level expression of human erythropoietin (EPO) in mammalian cells. Gene. 199:293–301.
   PubMed Web of Science ®Google Scholar
• Lindzen M, Carvalho S, Starr A, Ben-Chetrit N, Pradeep CR, Kostler WJ, Rabinkov A, Lavi S, Bacus SS, Yarden Y. A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis. Oncogene. 2011 Nov 21. doi: 10.1038/onc.2011.518.
   Google Scholar
• McIntyre E, Blackburn E, Brown PJ, Johnson CG, Gullick WJ. 2010. The complete family of epidermal growth factor receptors and their ligands are co-ordinately expressed in breast cancer. Breast Cancer Res Treat. 122:105–110.
   PubMed Web of Science ®Google Scholar
• Miyamoto S, Hirata M, Yamazaki A, Kageyama T, Hasuwa H, Mizushima H, Tanaka Y, Yagi H, Sonoda K, Kai M, Kanoh H, Nakano H, Mekada E. 2004. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res. 64:5720–5727.
   PubMedGoogle Scholar
• Muraoka-Cook RS, Feng SM, Strunk KE, Earp HS. 2008. ErbB4/HER4: role in mammary gland development, differentiation and growth inhibition. J Mammary Gland Biol Neoplasia. 13:235–246.
   Google Scholar
• Prickett TD, Agrawal NS, Wei X, Yates KE, Lin JC, Wunderlich JR, Cronin JC, Cruz P, Rosenberg SA, Samuels Y. 2009. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet. 41:1127–1132.
   PubMed Web of Science ®Google Scholar
• Sarup J, Jin P, Turin L, Bai X, Beryt M, Brdlik C, Higaki JN, Jorgensen B, Lau FW, Lindley P, Liu J, Ni I, Rozzelle J, Kumari R, Watson SA, Zhang J, Shepard HM. 2008. Human epidermal growth factor receptor (HER-1:HER-3) Fc-mediated heterodimer has broad antiproliferative activity in vitro and in human tumor xenografts. Mol Cancer Ther. 7:3223–3236.
   PubMed Web of Science ®Google Scholar
• Schoeberl B, Faber AC, Li D, Liang MC, Crosby K, Onsum M, Burenkova O, Pace E, Walton Z, Nie L, Fulgham A, Song Y, Nielsen UB, Engelman JA, Wong KK. 2010. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res. 70:2485–2494.
   PubMed Web of Science ®Google Scholar
• Srinivasan R, Poulsom R, Hurst HC, Gullick WJ. 1998. Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. J Pathol. 185:236–245.
   PubMed Web of Science ®Google Scholar
• Sundvall M, Iljin K, Kilpinen S, Sara H, Kallioniemi OP, Elenius K. 2008. Role of ErbB4 in breast cancer. J Mammary Gland Biol Neoplasia. 13:259–268.
   PubMed Web of Science ®Google Scholar
• Thogersen VB, Sorensen BS, Poulsen SS, Orntoft TF, Wolf H, Nexo E. 2001. A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients. Cancer Res. 61:6227–6233.
   PubMedGoogle Scholar
• Tsai MS, Shamon-Taylor LA, Mehmi I, Tang CK, Lupu R. 2003. Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer. Oncogene. 22:761–768.
   PubMed Web of Science ®Google Scholar
• Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yarden Y. 1996. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol. 16:5276–5287.
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. 2001. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137.
   PubMed Web of Science ®Google Scholar
• Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, Greene MI. 2007. ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest. 117:2051–2058.
   PubMed Web of Science ®Google Scholar